Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Golcadomide With Rituximab as a Bridging Therapy Prior to CAR-T for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)

NCT06834373 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06834373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06834373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Golcadomide With Rituximab as a Bridging Therapy Prior to CAR-T for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
April 2, 2025
Completion date
September 9, 2028
Enrollment
41 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma with irf4 rearrangement, recurrent aggressive b-cell non-hodgkin lymphoma, recurrent alk-positive large b-cell lymphoma, recurrent diffuse large b-cell lymphoma activated b-cell type, recurrent diffuse large b-cell lymphoma associated with chronic inflammation, recurrent diffuse large b-cell lymphoma germinal center b-cell type, recurrent diffuse large b-cell lymphoma, not otherwise specified, recurrent ebv-positive diffuse large b-cell lymphoma, not otherwise specified, recurrent grade 3b follicular lymphoma, recurrent high grade b-cell lymphoma with myc and bcl2 rearrangements, recurrent high grade b-cell lymphoma, not otherwise specified, recurrent intravascular large b-cell lymphoma, recurrent primary cutaneous diffuse large b-cell lymphoma, leg type, recurrent primary mediastinal large b-cell lymphoma, recurrent t-cell/histiocyte-rich large b-cell lymphoma, recurrent transformed non-hodgkin lymphoma, refractory aggressive b-cell non-hodgkin lymphoma, refractory alk-positive large b-cell lymphoma, refractory diffuse large b-cell lymphoma activated b-cell type, refractory diffuse large b-cell lymphoma associated with chronic inflammation, refractory diffuse large b-cell lymphoma germinal center b-cell type, refractory diffuse large b-cell lymphoma, not otherwise specified, refractory ebv-positive diffuse large b-cell lymphoma, not otherwise specified, refractory grade 3b follicular lymphoma, refractory high grade b-cell lymphoma with myc and bcl2 rearrangements, refractory high grade b-cell lymphoma, not otherwise specified, refractory intravascular large b-cell lymphoma, refractory primary cutaneous diffuse large b-cell lymphoma, leg type, refractory primary mediastinal large b-cell lymphoma, refractory t-cell/histiocyte-rich large b-cell lymphoma, refractory transformed non-hodgkin lymphoma